Table 2.
Changes in kidney function parameters after 6 months for the total population (n=45) and the group with stable medication use (n=29) and after 12 months for the total population
| Total population (n=45) | T0 | T6 | T12 | ||||
| Mean±SD median (IQR) | Mean±SD median (IQR) | n | P value | Mean±SD median (IQR) | n | P value | |
| eGFR (mL/min/1.73 m2) | 62.0 (55.5–65.0) | 69.0 (55.0–76.5) | 37 | 0.002* | 63.5 (58.5–71.0) | 22 | 0.067 |
| Albumin/creatinine ratio | 1.0 (0.4–1.8) | 0.9 (0.5–3.0) | 26 | 0.262 | 1.0 (0.2–2.7) | 18 | 0.286 |
| HbA1c (%) | 7.3±3.1 | 7.1±3.4 | 43 | 0.137 | 7.4±3.4 | 24 | 0.361 |
| Blood pressure (mmHg) | |||||||
| Systolic | 133.6±14.3 | 129.4±17.2 | 36 | 0.094 | 132.0±13.6 | 27 | 0.826 |
| Diastolic | 76.7±10.3 | 73.8±9.1 | 36 | 0.062 | 72.4±9.3 | 27 | 0.025* |
| MAP† | 95.7±10.2 | 92.3±10.4 | 36 | 0.044* | 92.3±9.3 | 27 | 0.106 |
| BMI (kg/m2) | 32.1±4.2 | 29.3±4.0 | 44 | <0.001* | 29.0±3.7 | 29 | <0.001* |
| Group with stable medication use (n=29) | Mean±SD median (IQR) | Mean±SD median (IQR) | n | P value | N/A | ||
| eGFR (mL/min/1.73 m2) | 62.0 (59.5–66.0) | 69.0 (60.0–77.0) | 25 | 0.006* | |||
| Albumin/creatinine ratio | 1.1 (0.3–3.1) | 0.9 (0.2–4.0) | 26 | 0.249 | |||
| HbA1c (%) | 7.2±3.1 | 7.0±3.5 | 27 | 0.248 | |||
| Blood pressure (mmHg) | |||||||
| Systolic | 134.6±16.3 | 128.9±18.5 | 24 | 0.074 | |||
| Diastolic | 77.7±10.5 | 73.1±10.1 | 24 | 0.016 | |||
| MAP† | 96.7±11.0 | 91.7±11.2 | 24 | 0.015 | |||
| BMI (kg/m2) | 31.5±4.0 | 28.8±4.0 | 29 | <0.001* | |||
*Significant result.
†MAP calculated as: (SBP+2(DBP))/3.
BMI, body mass index; DBP, diastolic blood pressure; IQR, interquartile range; MAP, mean arterial pressure; NA, not available; SBP, systolic blood pressure; SD, standard deviation.